ES2121881T3 - Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores. - Google Patents

Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.

Info

Publication number
ES2121881T3
ES2121881T3 ES93102895T ES93102895T ES2121881T3 ES 2121881 T3 ES2121881 T3 ES 2121881T3 ES 93102895 T ES93102895 T ES 93102895T ES 93102895 T ES93102895 T ES 93102895T ES 2121881 T3 ES2121881 T3 ES 2121881T3
Authority
ES
Spain
Prior art keywords
tumors
preparation
therapeutic agent
monoclonal anti
ganglioside antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93102895T
Other languages
English (en)
Inventor
Klaus Bosslet
Gerhard Seemann
Wolfgang Dippold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2121881T3 publication Critical patent/ES2121881T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION CONCIERNE A ANTICUERPOS MONOCLONALES, ALTAMENTE AVIDOS, QUE REACCIONAN ESPECIFICAMENTE CONTRA LOS GANGLIOSIDOS GD3 Y GQ1B, ASI COMO SU UTILIZACION PARA LA PRUEBA DE MELANOMAS Y OTROS TUMORES O TEJIDOS, QUE PRESENTAN GD3 Y GQ1B.
ES93102895T 1992-03-19 1993-02-25 Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores. Expired - Lifetime ES2121881T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4208795A DE4208795A1 (de) 1992-03-19 1992-03-19 Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum

Publications (1)

Publication Number Publication Date
ES2121881T3 true ES2121881T3 (es) 1998-12-16

Family

ID=6454438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93102895T Expired - Lifetime ES2121881T3 (es) 1992-03-19 1993-02-25 Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.

Country Status (12)

Country Link
US (1) US5730981A (es)
EP (1) EP0561183B1 (es)
JP (1) JP3513173B2 (es)
KR (1) KR100280948B1 (es)
AT (1) ATE169962T1 (es)
AU (1) AU666707B2 (es)
CA (1) CA2091967C (es)
DE (2) DE4208795A1 (es)
DK (1) DK0561183T3 (es)
ES (1) ES2121881T3 (es)
IL (1) IL105081A (es)
NO (1) NO315089B1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038252T2 (de) * 1999-09-30 2009-03-19 Kyowa Hakko Kogyo Co., Ltd. Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
GB2388777A (en) * 2000-12-08 2003-11-26 Childrens Memorial Hospital Compositions containing gangliosides for use in the treatment of skin disorders
KR100517613B1 (ko) * 2003-03-31 2005-09-28 엘지전자 주식회사 증기분사식 드럼세탁기
CN1894587A (zh) 2003-10-29 2007-01-10 财团法人熊本高新技术产业财团 恶性黑色素瘤(melanoma)的诊断试剂
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
WO2016185035A1 (en) * 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
CA1339798C (en) * 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
US5055559A (en) * 1986-02-20 1991-10-08 Oncogen Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors
EP0234122A3 (en) * 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
JP2789469B2 (ja) * 1988-07-16 1998-08-20 メクト株式会社 ガングリオシドＧＱ▲下１▼▲下ｂ▼およびＧＴ▲下１▼▲下ａ▼を認識するモノクローナル抗体
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
ES2098304T3 (es) * 1990-11-30 1997-05-01 Kyowa Hakko Kogyo Kk Anticuerpos monoclonales frente a cadenas de hidratos de carbono glucolipidicas.

Also Published As

Publication number Publication date
ATE169962T1 (de) 1998-09-15
JPH0646882A (ja) 1994-02-22
EP0561183B1 (de) 1998-08-19
US5730981A (en) 1998-03-24
EP0561183A1 (de) 1993-09-22
KR930019820A (ko) 1993-10-19
KR100280948B1 (ko) 2001-04-02
CA2091967C (en) 2006-11-07
NO930990D0 (no) 1993-03-18
NO930990L (no) 1993-09-20
IL105081A0 (en) 1993-07-08
AU666707B2 (en) 1996-02-22
DE4208795A1 (de) 1993-09-23
AU3531893A (en) 1993-09-23
CA2091967A1 (en) 1993-09-20
DE59308875D1 (de) 1998-09-24
JP3513173B2 (ja) 2004-03-31
IL105081A (en) 1998-01-04
DK0561183T3 (da) 1999-05-25
NO315089B1 (no) 2003-07-07

Similar Documents

Publication Publication Date Title
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2166807T3 (es) Piridazinonas y su uso como fungicidas.
ES2176700T3 (es) Composiciones para la piel.
ES2167391T3 (es) Inmunoconjugados ii.
ES2115733T3 (es) Composicion antialergica para uso oftalmico o nasal.
ATE160285T1 (de) Haarfärbemittel
ES2152998T3 (es) Agente anticomplementario obtenido a partir de fucanos de algas pardas.
PT758248E (pt) Formulacoes para o factor ix
ES2140409T3 (es) Agente de contraste para rayos x.
ES2032016T3 (es) Un procedimiento para la produccion de las 13, 14-ceto-pgfs.
BR9908223A (pt) Método para reduzir celulite na pele de mamìferos
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
ES520988A0 (es) Procedimiento para la preparacion de nuevos 6,11-dihidro-dibenzo-(b,e)-tiepin-11-n-alcohilnorescopin-eteres.
ES2052881T3 (es) Agentes reductores de la presion sanguinea.
BR9806688A (pt) Composição cosmética e agente inibidor da melanogênese
ES2119325T3 (es) Compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ES2115060T3 (es) Microparticulas, procedimiento para su produccion, asi como la utilizacion de estas para finalidades de diagnostico.
TR199901104T2 (xx) Farmas�tik bile�ikler.
CO5221025A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
MX9604765A (es) Derivados de 5-heterociclico 1,5-benzodiazepinas que modulan la cck o gastrina.
CU23269A3 (es) Bromhidrato de eletriptan monohidratado
ES2191062T3 (es) Derivados de pirazolil-pirazol sustituidos, procedimientos para su preparacion y su utilizacion como agentes con accion herbicida.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 561183

Country of ref document: ES